ALB and Hepatic fibrosis: Although each trial showed an increase in ALB levels after MSCs treatment for liver fibrosis, there was significant heterogeneity [p < 0.00001, I2 = 86%; SMD = −2.90, 95% CI (−3.70, −2.11), p < 0.00001].